F.T.C. Slams Middlemen for High Drug Prices, Reversing Hands-Off Approach

The Federal Trade Commission on Tuesday sharply criticized pharmacy benefit managers, saying in a scathing 71-page report that “these powerful middlemen may be profiting by inflating drug costs and squeezing Main Street pharmacies.” The regulator’s study signals a significant ramping up of its scrutiny of benefit managers under the agency’s chair, Lina Khan.